Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.Can J Cardiol. Mar 2020; 36: 322-334https://doi.org/10.1016/j.cjca.2019.12.034
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.N Engl J Med. Sep 2018; 379: 1007-1016https://doi.org/10.1056/NEJMoa1805689
Technology CAfDaH. Canadian Drug Expert Reimbursement Recommendations - Tafamidis Meglumine. Common Drug Review. Ottawa, Ontario, Canada 2020. p. 1-8.
- The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.Circulation. Nov 06 2007; 116: 2216-2233https://doi.org/10.1161/CIRCULATIONAHA.107.186093
- Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis.Am J Cardiol. May 15 2014; 113: 1723-1727https://doi.org/10.1016/j.amjcard.2014.02.030